This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

6 Sep 2021

3i Group backs ten23 health to create global CDMO focused on biopharma injectables

The new Switzerland-based CDMO differentiates itself by its sustainable vision of making a positive impact for people and planet

A new, globally operating CDMO, ten23 health, funded by 3i Group and specialising in biopharmaceutical injectables, has been launched.

ten23 health will support biotech start-ups and established pharmaceutical customers in developing safe injectable biopharmaceutical drugs for patients.

The CDMO's core service offering includes formulation development, drug product development and manufacturing, as well as testing services for sterile pharmaceutical products.

Headquartered in Basel, Switzerland — a vibrant life sciences cluster — ten23 health has started operating on the Rosental campus “Rosental Mitte”, taking over a fully operational lab and office building from Elanco.

The building includes approximately 4,000 m2 of lab and office space, and will provide a work environment for 150 full-time employees. Benefiting from the talented workforce in the Basel area, ten23 health has hired a team of accomplished leaders, scientists and technicians.

Heading the new company is Prof. Dr Hanns-Christian Mahler, who was the former Head of Drug Product Services at Lonza.

The new company says it is keen to differentiate itself by making a positive impact not just for people, but also for the planet, and aims for a net zero emissions target from inception.

Related News